**WIPO Daejeon 2017 Workshop on PCT National Phase Examination and Work-Sharing**

The exercises include case studies of selected PCT national phase entries which are listed in a separately distributed excel table (as soft copy). You are requested to research these cases based on the instructions given below and fill the columns E to P of the table (using an electronic copy of the table). At the end of the workshop you will be given a completed table with solutions.

In a first part, the family relations and priority claims are to be researched. A 2nd part researches the examination status in different national phases, a third part compares claims granted in different national phases, and a fourth part compares the prior art citations applied in different national phases. The latter will help to understand why claims granted by different examiners may differ.

The top record of the table (1st case) gives an example of how the researched information should be recorded in the table.

**Part 4 (comparing citations from different national phases)**

- check if the ISR includes only A citations, and record that in column M; indicate as well the country code of the ISA;

- check if the ISR includes observations (Box III) on the unity of patent (column N of the table);

- check if additional citations were used in the different national phases (column O of the table; whenever you find a national phase where an examiner did a supplementary search, please enter the country code of that national phase and record one sample citation from that examiner which is not in the ISR), in particular:

- check if there is a published supplementary EP search report (please enter 'EP-A4' in the table if that is the case),

- use the CCD for finding citations not included in the ISR,

- where the CCD includes no records for a country in the patent family, you may check front pages of grant publications for citations.

#6(plant cultivation); #38(Newcastle viruses); #39(treating pellet fines); #41(RORC2 inhibitors); #42(composite barrier); #20(IAP inhibitors; #35 (portion capsule); #30(surface reacted carbonate)